LLY

877.97

+0.77%↑

UNH

526.48

-0.54%↓

JNJ

153.08

-0.26%↓

NVO

86.38

-0.88%↓

MRK

87.25

-0.84%↓

LLY

877.97

+0.77%↑

UNH

526.48

-0.54%↓

JNJ

153.08

-0.26%↓

NVO

86.38

-0.88%↓

MRK

87.25

-0.84%↓

LLY

877.97

+0.77%↑

UNH

526.48

-0.54%↓

JNJ

153.08

-0.26%↓

NVO

86.38

-0.88%↓

MRK

87.25

-0.84%↓

LLY

877.97

+0.77%↑

UNH

526.48

-0.54%↓

JNJ

153.08

-0.26%↓

NVO

86.38

-0.88%↓

MRK

87.25

-0.84%↓

LLY

877.97

+0.77%↑

UNH

526.48

-0.54%↓

JNJ

153.08

-0.26%↓

NVO

86.38

-0.88%↓

MRK

87.25

-0.84%↓

Search

AbbVie Inc

Cerrado

Sector Salud

190.7 -1.19

Resumen

Variación precio

24h

Actual

Mínimo

190.41

Máximo

193.64

Métricas clave

By Trading Economics

Ingresos

-1.6B

-22M

Ventas

640M

15B

P/B

Media del Sector

61.995

59.362

BPA

2.16

Rentabilidad por dividendo

3.692

Margen de beneficio

-0.146

EBITDA

1B

6B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+7.43 upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

3.69%

2.35%

Próximas Ganancias

25 abr 2025

Fecha Próximo Dividendo

14 feb 2025

Próxima Fecha de Ex Dividendo

11 abr 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

325B

Apertura anterior

191.89

Cierre anterior

190.7

Noticias sobre sentimiento de mercado

By Acuity

19%

81%

35 / 393 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

AbbVie Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

31 ene 2025, 13:28 UTC

Ganancias

AbbVie 4Q Revenue Tops Estimates as Skyrizi, Rinvoq Growth Surges

6 feb 2025, 13:25 UTC

Principales Noticias
Ganancias

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

6 feb 2025, 12:00 UTC

Ganancias

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

5 feb 2025, 12:00 UTC

Principales Noticias

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

31 ene 2025, 15:50 UTC

Principales Noticias
Ganancias

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

31 ene 2025, 13:51 UTC

Ganancias

AbbVie Jumps After Its Powerhouses, Skyrizi And Rinvoq, Continued To Dominate -- IBD

31 ene 2025, 13:47 UTC

Principales Noticias
Ganancias

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

31 ene 2025, 13:24 UTC

Charlas de Mercado
Ganancias

AbbVie Gets More Upbeat on Skyrizi, Rinvoq -- Market Talk

31 ene 2025, 12:46 UTC

Ganancias

AbbVie's Stock Pops 4% After Earnings Beat Estimates And Company Offers Upbeat View Of 2025 -- MarketWatch

31 ene 2025, 12:39 UTC

Ganancias

AbbVie 4Q Global Rinvoq Net Revenue $1.83B, Up 46.2% >ABBV

31 ene 2025, 12:38 UTC

Ganancias

AbbVie: Expect 2025 Revenue to Exceed Previous Peak >ABBV

31 ene 2025, 12:38 UTC

Ganancias

AbbVie Now Sees Aesthetics Delivering High-Single-Digit Compound Annual Revenue Growth From 2025-2029 >ABBV

31 ene 2025, 12:37 UTC

Ganancias

AbbVie Raises 2027 Combined Sales Outlook for Skyrizi, Rinvoq to More Than $31B >ABBV

31 ene 2025, 12:37 UTC

Ganancias

AbbVie Reaffirms Expectations for High-Single-Digit Compound Annual Revenue Growth Rate Through 2029 >ABBV

31 ene 2025, 12:36 UTC

Ganancias

AbbVie: 4Q Revenue Rose 6.1% on Operational Basis >ABBV

31 ene 2025, 12:36 UTC

Ganancias

AbbVie 4Q Loss $22M >ABBV

31 ene 2025, 12:36 UTC

Ganancias

AbbVie 4Q U.S. HUMIRA Rev $1.25B >ABBV

31 ene 2025, 12:36 UTC

Ganancias

AbbVie 4Q Global Net Rev From Oncology Portfolio $1.69B >ABBV

31 ene 2025, 12:36 UTC

Ganancias

AbbVie 4Q Global Skyrizi Rev $3.78B >ABBV

31 ene 2025, 12:36 UTC

Ganancias

AbbVie 4Q International HUMIRA Rev $436M >ABBV

31 ene 2025, 12:36 UTC

Ganancias

AbbVie 4Q Adj EPS $2.16 >ABBV

31 ene 2025, 12:36 UTC

Ganancias

AbbVie Sees FY Adj EPS $12.12-Adj EPS $12.32 >ABBV

31 ene 2025, 12:36 UTC

Ganancias

AbbVie 4Q Loss/Shr 2c >ABBV

31 ene 2025, 12:36 UTC

Ganancias

AbbVie 4Q Global IMBRUVICA Rev $848M >ABBV

31 ene 2025, 12:36 UTC

Ganancias

AbbVie 4Q Rev $15.1B >ABBV

23 ene 2025, 14:17 UTC

Adquisiciones, fusiones, absorciones

AbbVie Completes Acquisition Of Nimble Therapeutics >ABBV

21 ene 2025, 17:48 UTC

Ganancias

Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere -- Here's Why -- IBD

10 ene 2025, 13:36 UTC

Adquisiciones, fusiones, absorciones

AbbVie Estimates Non-Cash After-Tax Intangible Asset-Impairment Charge of About $3.5B >ABBV

10 ene 2025, 13:35 UTC

Adquisiciones, fusiones, absorciones

AbbVie to Record Impairment Charge Related to the Emraclidine Intangible Asset From Acquisition of Cerevel Therapeutics

1 ene 2025, 08:30 UTC

Principales Noticias

Drug-Trial Results Could Shake Up Pharma Stocks in 2025. Watch Eli Lilly, Pfizer, and More. -- Barrons.com

Comparación entre iguales

Cambio de precio

AbbVie Inc Esperado

Precio Objetivo

By TipRanks

7.43% repunte

Estimación a 12 meses

Media 207.3 USD  7.43%

Máximo 239 USD

Mínimo 165 USD

De acuerdo con 20 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AbbVie Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

20 ratings

15

Comprar

5

Mantener

0

Vender

Puntuación técnica

By Trading Central

170.67 / 193.38Soporte y Resistencia

Corto Plazo

Very Strong Bullish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

35 / 393 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de AbbVie Inc

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.